News Release

Yamanouchi Pharmaceutical Co., Ltd.

YAMANOUCHI SHAKLEE PHARMA AND JOHNSON & JOHNSON-MERCK SIGN WOWTAB(R) DEVELOPMENT AGREEMENT

June 8, 1998

Palo Alto, CA, (June 8, 1998)---Yamanouchi Shaklee Pharma announced today that it has entered into an agreement with Johnson & Johnson-Merck Consumer Pharmaceuticals Co. for utilization of its WOWTAB(R) quick-dissolving, without-water tablet technology in the development and commercialization of an OTC product.

"The development and licensing of proprietary drug delivery technologies continues to be a key element of Yamanouchi Shaklee Pharma's business strategy," said Dan Green, Vice President of Business Development. "This agreement with J&J-Merck, the market leader in OTC H2-antagonist therapy, marks another significant addition to our portfolio of Rx and OTC drug delivery programs." The company is actively marketing WOWTAB(R), the first patented quick-dissolving technology designed for conventional manufacturing and packaging equipment, plus the OCASTM (Oral Controlled Absorption System) controlled-release technology, and has additional technologies in its development pipeline.

Yamanouchi Shaklee Pharma, located in the Stanford Research Park in Palo Alto, California, is a division of San Francisco-based Shaklee Corporation. Shaklee Corporation became a wholly owned subsidiary of Yamanouchi Pharmaceutical Co., Ltd. in 1989. With operations worldwide, Yamanouchi ranks third in sales in the Japanese pharmaceutical market.